KeChow Pharma received NMPA approval for Tunlametinib, the first targeted therapy approved in China for NRAS-mutated advanced melanoma.
Shanghai Kechow Pharma, Inc
Shanghai Kechow Pharma, Inc. is a pharmaceutical company that integrates drug discovery, clinical development, and sales of new anti-cancer drugs. It focuses on developing innovative drugs in oncology and free radical-related diseases.